MCID: WLD002
MIFTS: 61

Waldenstrom Macroglobulinemia

Categories: Rare diseases, Neuronal diseases, Blood diseases, Immune diseases

Aliases & Classifications for Waldenstrom Macroglobulinemia

MalaCards integrated aliases for Waldenstrom Macroglobulinemia:

Name: Waldenstrom Macroglobulinemia 38 53 25 29 55 40 73 25 59
Macroglobulinemia of Waldenstrom 53 25
Malignant Lymphoma - Lymphoplasmacytic 73
Waldenstrom's Macroglobulinaemia 53
Waldenstrom's Macroglobulinemia 25
Lymphoplasmacytic Lymphoma 53
Waldenstrom's Syndrome 53
Wm 25

Characteristics:

Orphanet epidemiological data:

59
waldenström macroglobulinemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (France),1-9/1000000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/100000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:



Summaries for Waldenstrom Macroglobulinemia

NIH Rare Diseases : 53 Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy, fever, Raynaud's phenomenon, and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition. Treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues.

MalaCards based summary : Waldenstrom Macroglobulinemia, also known as macroglobulinemia of waldenstrom, is related to lymphoplasmacytic lymphoma and macroglobulinemia. An important gene associated with Waldenstrom Macroglobulinemia is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are Akt Signaling and Development Angiotensin activation of ERK. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are renal insufficiency and gingival bleeding

Wikipedia : 76 Waldenström\'s macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma, is a type of cancer... more...

Related Diseases for Waldenstrom Macroglobulinemia

Diseases in the Waldenstrom Macroglobulinemia family:

Macroglobulinemia, Waldenstrom 1 Macroglobulinemia, Waldenstrom 2

Diseases related to Waldenstrom Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 lymphoplasmacytic lymphoma 32.9 CD40LG CXCR4 MYD88 PAX5
2 macroglobulinemia 32.9 CD40LG CXCR4 MYD88 PAX5
3 myeloma, multiple 30.3 CD40 CD40LG CXCR4
4 hematologic cancer 29.9 CD40LG CXCR4 PAX5 ZAP70
5 mantle cell lymphoma 29.8 BCL2 CD40 CD40LG PAX5
6 b-cell lymphomas 29.3 BCL2 CD40 MS4A1 PAX5
7 lymphoma, non-hodgkin, familial 28.5 BCL2 CD40 CD40LG CXCR4 MS4A1 PAX5
8 leukemia, chronic lymphocytic 25.9 BCL2 CD40 CD40LG CXCR4 IGHM MIR155
9 macroglobulinemia, waldenstrom 1 11.2
10 heavy chain disease 10.8 CD40LG MYD88
11 monoclonal paraproteinemia 10.7 CD40LG MYD88
12 light fixation seizure syndrome 10.6 CD40 CD40LG
13 cryoglobulinemia, familial mixed 10.6 CD40LG IGHM
14 intraocular lymphoma 10.6 CXCR4 PAX5
15 immunodeficiency with hyper-igm, type 4 10.6 CD40 CD40LG
16 plasma protein metabolism disease 10.6 CD40LG CXCR4 MYD88
17 hyperimmunoglobulin syndrome 10.6 CD40 CD40LG
18 gamma heavy chain disease 10.6 CD40LG MYD88
19 cd40 ligand deficiency 10.5 CD40 CD40LG
20 marginal zone b-cell lymphoma 10.5 BCL2 CD40LG MYD88
21 immune defect due to absence of thymus 10.5 CD40LG ZAP70
22 immunodeficiency with hyper-igm, type 3 10.5 CD40 CD40LG
23 immunodeficiency with hyper-igm, type 1 10.4 CD40 CD40LG
24 cll/sll 10.4 PAX5 ZAP70
25 toxoplasmosis 10.4 CD40 CD40LG MYD88
26 cold agglutinin disease 10.3 IGHM MS4A1
27 immune deficiency disease 10.3 CD40 CD40LG CXCR4
28 lymphoma 10.3
29 byssinosis 10.2 CD40LG HAS1
30 combined immunodeficiency, x-linked 10.2 CD40 CD40LG ZAP70
31 b cell prolymphocytic leukemia 10.2 MS4A1 ZAP70
32 exanthema subitum 10.2 CD40 CD40LG
33 primary central nervous system lymphoma 10.1 BCL2 IGHM MYD88 PAX5
34 pleuropneumonia 10.0 CD40LG MYD88
35 autoimmune lymphoproliferative syndrome, type v 10.0
36 leukemia 10.0
37 retinitis 10.0
38 leukemia, chronic lymphocytic 2 9.9
39 retinal detachment 9.9
40 temporal arteritis 9.9
41 lymphoma, hodgkin, classic 9.9
42 polycythemia vera 9.9
43 aging 9.9
44 stomatin-like protein-2, hyperphosphorylation of 9.9
45 pulmonary hypertension 9.9
46 diffuse large b-cell lymphoma 9.9
47 hepatitis 9.9
48 retinal vein occlusion 9.9
49 sinusitis 9.9
50 colitis 9.9

Comorbidity relations with Waldenstrom Macroglobulinemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Neutropenia

Graphical network of the top 20 diseases related to Waldenstrom Macroglobulinemia:



Diseases related to Waldenstrom Macroglobulinemia

Symptoms & Phenotypes for Waldenstrom Macroglobulinemia

Human phenotypes related to Waldenstrom Macroglobulinemia:

59 32 (show all 46)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
2 gingival bleeding 59 32 frequent (33%) Frequent (79-30%) HP:0000225
3 hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000365
4 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
5 proptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000520
6 retinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0000573
7 cutis marmorata 59 32 occasional (7.5%) Occasional (29-5%) HP:0000965
8 purpura 59 32 occasional (7.5%) Occasional (29-5%) HP:0000979
9 pallor 59 32 frequent (33%) Frequent (79-30%) HP:0000980
10 urticaria 59 32 occasional (7.5%) Occasional (29-5%) HP:0001025
11 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
12 stroke 59 32 occasional (7.5%) Occasional (29-5%) HP:0001297
13 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
14 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
15 abnormality of neutrophils 59 32 frequent (33%) Frequent (79-30%) HP:0001874
16 normocytic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001897
17 leukemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001909
18 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
19 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
20 malabsorption 59 32 occasional (7.5%) Occasional (29-5%) HP:0002024
21 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
22 migraine 59 32 occasional (7.5%) Occasional (29-5%) HP:0002076
23 respiratory insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002093
24 pulmonary infiltrates 59 32 occasional (7.5%) Occasional (29-5%) HP:0002113
25 pleural effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0002202
26 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
27 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
28 vertigo 59 32 frequent (33%) Frequent (79-30%) HP:0002321
29 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
30 vasculitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002633
31 lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0002665
32 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
33 recurrent infections 59 32 occasional (7.5%) Occasional (29-5%) HP:0002719
34 elevated erythrocyte sedimentation rate 59 32 occasional (7.5%) Occasional (29-5%) HP:0003565
35 reduced consciousness/confusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0004372
36 cranial nerve paralysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0006824
37 abnormality of the retinal vasculature 59 32 occasional (7.5%) Occasional (29-5%) HP:0008046
38 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
39 edema of the lower limbs 59 32 occasional (7.5%) Occasional (29-5%) HP:0010741
40 multifocal epileptiform discharges 59 32 occasional (7.5%) Occasional (29-5%) HP:0010841
41 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
42 periorbital edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0100539
43 hypercoagulability 59 32 frequent (33%) Frequent (79-30%) HP:0100724
44 cryoglobulinemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100778
45 waldenstrom macroglobulinemia 59 Very frequent (99-80%)
46 monoclonal immunoglobulin m proteinemia 32 hallmark (90%) HP:0005508

Drugs & Therapeutics for Waldenstrom Macroglobulinemia

Drugs for Waldenstrom Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
4
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
7
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 147-94-4 6253
8
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
9
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 50-24-8 5755
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
15 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
25 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
26 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
35 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antibodies Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Immunoglobulins Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
45 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Angiogenesis Inhibitors Phase 4,Phase 1,Phase 2
47 Angiogenesis Modulating Agents Phase 4,Phase 1,Phase 2
48 Methylprednisolone acetate Phase 4,Phase 2,Phase 1,Not Applicable
49 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 1,Not Applicable
50 Neuroprotective Agents Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 472)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
12 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
13 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
14 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
15 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
18 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
22 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
25 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
26 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
27 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
28 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
29 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
30 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
31 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
32 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
33 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo Active, not recruiting NCT01461928 Phase 3 Chemotherapy (Induction Period);Rituximab
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
36 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
37 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
38 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
39 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
40 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
41 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
42 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
43 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
44 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
45 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
46 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid
47 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
48 Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
49 Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia Completed NCT02092909 Phase 1, Phase 2 IMO-8400
50 Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00777738 Phase 2 BORTEZOMIB

Search NIH Clinical Center for Waldenstrom Macroglobulinemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Waldenstrom Macroglobulinemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Waldenstrom Macroglobulinemia:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Waldenstrom Macroglobulinemia:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Waldenstrom Macroglobulinemia

Genetic tests related to Waldenstrom Macroglobulinemia:

# Genetic test Affiliating Genes
1 Waldenstrom Macroglobulinemia 29 MYD88

Anatomical Context for Waldenstrom Macroglobulinemia

MalaCards organs/tissues related to Waldenstrom Macroglobulinemia:

41
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Liver, Kidney

Publications for Waldenstrom Macroglobulinemia

Articles related to Waldenstrom Macroglobulinemia:

(show top 50) (show all 138)
# Title Authors Year
1
Waldenstrom macroglobulinemia involving the superior rectus muscle. ( 29780960 )
2018
2
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. ( 28583038 )
2018
3
Dexamethasone, rituximab and cyclophosphamide for relapsedA and/or refractory and treatment-naA^ve patients with Waldenstrom macroglobulinemia. ( 28786474 )
2017
4
UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT. ( 28106626 )
2017
5
A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission. ( 28883220 )
2017
6
Significances of MYD88(L265P) and CXCR4(WHIM) Mutations in Waldenstrom Macroglobulinemia. ( 28877839 )
2017
7
Waldenstrom macroglobulinemia presenting as a bilateral subdural chronic hematoma. ( 28262409 )
2017
8
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. ( 28548645 )
2017
9
EDTA-induced pseudothrombocytosis and citrate-induced platelet agglutination in a patient with Waldenstrom macroglobulinemia. ( 28781833 )
2017
10
A Case of Waldenstrom Macroglobulinemia with Temporary Appearance of 7S IgM Half Molecule. ( 28627827 )
2017
11
Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. ( 26942591 )
2016
12
Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). ( 27836860 )
2016
13
Learning from Waldenstrom Macroglobulinemia. ( 27825458 )
2016
14
A 44-Year-Old Man with Waldenstrom Macroglobulinemia and Bilateral Maxillary Sinusitis. ( 27840358 )
2016
15
Novel therapeutic targets in Waldenstrom macroglobulinemia. ( 27825468 )
2016
16
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. ( 27696269 )
2016
17
Waldenstrom macroglobulinemia: prognosis and management. ( 26849012 )
2016
18
Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. ( 27268124 )
2016
19
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. ( 27813535 )
2016
20
Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. ( 27722129 )
2016
21
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia. ( 25703132 )
2015
22
Waldenstrom Macroglobulinemia Mimicking Temporal Arteritis. ( 25996301 )
2015
23
Waldenstrom macroglobulinemia: prognosis and management. ( 25815903 )
2015
24
Characteristic OCT Pattern in Waldenstrom Macroglobulinemia. ( 25871872 )
2015
25
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. ( 26139427 )
2015
26
Detection of erythrocytes in patients with Waldenstrom macroglobulinemia using atomic force microscopy. ( 24675428 )
2014
27
Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line. ( 24189269 )
2014
28
Waldenstrom macroglobulinemia: genetics dictates clinical course. ( 24786453 )
2014
29
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. ( 25060991 )
2014
30
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. ( 24622324 )
2014
31
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. ( 24553177 )
2014
32
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. ( 24716234 )
2014
33
A new era for Waldenstrom macroglobulinemia: MYD88 L265P. ( 23723443 )
2013
34
Waldenstrom macroglobulinemia presenting as isolated persistent epistaxis: a very rare presentation. ( 24427564 )
2013
35
Waldenstrom macroglobulinemia presenting with pancreatic mass: a case report and review of literature. ( 23306344 )
2013
36
A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia. ( 23773449 )
2013
37
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. ( 23861223 )
2013
38
Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia. ( 23355206 )
2013
39
MYD88 L265P mutation in Waldenstrom macroglobulinemia. ( 23532735 )
2013
40
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). ( 24004667 )
2013
41
Choice of therapy for patients with Waldenstrom macroglobulinemia. ( 23233705 )
2013
42
Waldenstrom macroglobulinemia with a durable clinical response to epoetin beta. ( 22260157 )
2012
43
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. ( 23048077 )
2012
44
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. ( 22879385 )
2012
45
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. ( 22099500 )
2012
46
Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data. ( 22100692 )
2012
47
Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual. ( 22404949 )
2012
48
Progression in smoldering Waldenstrom macroglobulinemia: long-term results. ( 22451426 )
2012
49
Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. ( 22139816 )
2012
50
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. ( 21732338 )
2012

Variations for Waldenstrom Macroglobulinemia

Expression for Waldenstrom Macroglobulinemia

Search GEO for disease gene expression data for Waldenstrom Macroglobulinemia.

Pathways for Waldenstrom Macroglobulinemia

Pathways related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.15 BCL2 CD40 CD40LG CXCR4 MYD88 ZAP70
2
Show member pathways
12.65 CD40 CD40LG CXCR4 IGHM ZAP70
3
Show member pathways
12.43 CD40 CD40LG MYD88 ZAP70
4 12.25 BCL2 MIR155 MIR206 MIR494
5
Show member pathways
12.2 BCL2 CD40 CD40LG MYD88
6 12.17 CD40LG CXCR4 MYD88 PAX5 ZAP70
7
Show member pathways
12.01 BCL2 CD40 CD40LG MYD88
8 12 BCL2 CD40LG CXCR4
9
Show member pathways
11.5 BCL2 CD40 CD40LG
10 11.33 BCL2 CD40 CD40LG MYD88 ZAP70
11 11.27 CD40 CD40LG MYD88
12 11.07 CD40 CD40LG ZAP70
13 11.05 CD40 CD40LG
14 11.01 CD40 CD40LG
15 10.85 CD40 CD40LG ZAP70
16 10.75 CD40 CD40LG CXCR4 MS4A1 PAX5

GO Terms for Waldenstrom Macroglobulinemia

Cellular components related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD40 CD40LG IGHM MS4A1

Biological processes related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.73 CD40 CD40LG CXCR4 MYD88
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.58 CD40 CD40LG MYD88
3 humoral immune response GO:0006959 9.5 BCL2 MS4A1 PAX5
4 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.48 MIR155 MIR494
5 positive regulation of interleukin-12 production GO:0032735 9.46 CD40 CD40LG
6 positive regulation of endothelial cell apoptotic process GO:2000353 9.37 CD40 CD40LG
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.33 MIR155 MIR206 MIR494
8 regulation of immunoglobulin secretion GO:0051023 9.26 CD40 CD40LG
9 B cell activation GO:0042113 9.13 CD40 MS4A1 ZAP70
10 B cell proliferation GO:0042100 8.92 BCL2 CD40 CD40LG MS4A1

Sources for Waldenstrom Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....